Last reviewed · How we verify
NCT06298526: UdSA_AN
Auditory Sensory Attenuation in Anorexia Nervosa
trial in Anorexia Nervosa in 31 participants. Completed in 30 June 2025.
29 February 2024
Quick facts
| Lead sponsor | Istituto Auxologico Italiano |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 31 |
| Start date | 1 March 2023 |
| Primary completion | 29 February 2024 |
| Estimated completion | 30 June 2025 |
| Sites | 1 location across Italy |
Conditions studied
- Anorexia Nervosa — all drugs for Anorexia Nervosa →
Sponsor
Istituto Auxologico Italiano — full company profile →
Who can join
18 and older, female only, with Anorexia Nervosa. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational cross-sectional study is to test the sensory attenuation effect with auditory stimuli comparing women affected by anorexia nervosa and healthy-weight women. Specifically, the study aims to test whether the sensory attenuation effect (i.e., the perceived loudness of a self-generated sound is weaker than when another person produces the same sound): i) is observed in anorexia nervosa ii) it can be modulated in interactive action contexts, as was previously observed in healthy participants. Participants will compare the loudness of target sound with a comparison tone, which can be prompt by the participant by pressing a button on their own will (i.e., individual context) or upon the experimenter\'s signal (i.e., interactive context); externally-generated sounds are produced in the opposite way.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06298526
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Anorexia Nervosa
Currently open trials in the same condition.
- NCT07169747 — Safety, Therapeutic Potential, and Mechanisms of Two Psilocybin Doses, Administered With Psychological Support in Young · Phase 2 · recruiting
- NCT07237607 — Developing an Artificial Intelligence (AI) Chatbot for Adolescents and Young Adults With Eating Disorders · NA · recruiting
- NCT07188155 — Adapting Exposure for Adolescent AN · NA · recruiting
- NCT07143981 — The Fecal Microbiome Transplant (FMT) Study for Anorexia Nervosa · recruiting
- NCT07311356 — Prognosis of Early-onset Anorexia Nervosa · recruiting
Other Istituto Auxologico Italiano trials
Trials by the same sponsor.
- NCT07384962 — ORION Study: Mesh Position and Risk During Subsequent Minimally Invasive Abdominal Surgery · not yet recruiting
- NCT07358832 — Neuromodulation Through Multisensory Stimulation for Visual Field Deficits in the Subacute Stage of Disease · NA · recruiting
- NCT07302321 — Needs of ALS Patients With C9orf72 Mutation and Their Caregivers · recruiting
- NCT07162740 — Implantable Loop Recorder and Cardioneuroblation · not yet recruiting
- NCT07312240 — LONgitudinal and Integrated Evaluation of Biomarkers in reLation to phenotYpe in ALS · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06298526 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Istituto Auxologico Italiano
- Last refreshed: 8 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06298526.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing